Trizepatide and other glp1ra as a novel treatment for patients with lipodystrophy
AssigneeRutgers, The State University of New Jersey
InventorsChristopher Buettner, Svetlana Ten
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating congenital generalized lipodystrophy using tirzepatide. The disclosure also provides methods for treating a disease in a patient characterized by leptin and leptin signaling deficiency.
Claims20
A method of treating generalized lipodystrophy in a patient in need thereof, the method comprising administering a therapeutically effective amount of a GLP-1 receptor agonist to the patient.
A method of treating a disease in a patient characterized by leptin and leptin signaling deficiency, the method comprising administering a therapeutically effective amount of a GLP-1 receptor agonist to the patient.
Dependencies are inferred from the claim text.